Drug Trial Radar · NCT07362940
A Phase Ⅰ/Ⅱa Clinical Study of GEN-725 in Combination With Dositinib
Last checked: Nov 19, 2026Latest source record: Jan 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
110
Planned (sponsor's estimate)
Start
Nov 27, 2025
Primary completion
Jul 31, 2027
Study completion Dec 31, 2028
Sponsor
- Lead sponsor
- Henan Genuine Biotech Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jan 23, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label phase I/phase II clinical study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of GEN-725 in combination with Dositinib in participants with locally advanced or metastatic EGFR-mutant non-small cell lung cancer.
Conditions
- Non-Small Cell Lung Cancer
Interventions
GEN-725 tablets + Dositinib mesylate tabletsDrug
Dose-escalation part (Phase Ⅰ): Subjects will receive once-daily oral administration of GEN-725 tablets in combination with Dositinib mesylate tablets on an empty stomach. GEN-725 will be administered at a dose of 6 mg or 9 mg, and Dositinib will be administered at a dose of 80 mg or 160 mg. Both drugs should be taken concurrently. The treatment will continue until the first occurrence of any of the following: disease progression, unacceptable toxicity, withdrawal of consent, or investigator's determination of no further clinical benefit. Dose-expansion part (Phase Ⅱa): Subjects will receive once-daily oral administration of GEN-725 tablets in combination with Dositinib mesylate tablets or Dositinib mesylate tablets alone on an empty stomach. The dose will be selected based on the outcome of dose-escalation phase. The treatment will continue until the first occurrence of any criterion that was specified in the dose-escalation part.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Subjects with Dose Limiting Toxicity (DLT) in Phase ⅠTime frame: From Day 1 to Day 21 of Cycle1 (each cycle is 21 days).
- Incidence and severity of adverse events (AEs) in Phase Ⅰ and Phase ⅡaTime frame: From the time of informed consent until 28 days after the last administration of the study drugs.
- Objective Response Rate (ORR) in Phase ⅡaTime frame: Every 6 weeks during the first year and every 12 weeks thereafter, up to 5 years.
- Intracranial Objective Response Rate (iORR) in Phase ⅡaTime frame: Every 6 weeks during the first year and every 12 weeks thereafter, up to 5 years.
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Beijing Cancer Hospital
Beijing, China · Recruiting
Hunan Cancer Hospital
Changsha, China · Not yet recruiting
Cancer Hospital Affiliated to Shandong First Medical University (Shandong Cancer Hospital, Shandong cancer prevention and treatment institute)
Jinan, China · Not yet recruiting
The First Affiliated Hospital of Xiamen University
Xiamen, China · Not yet recruiting
Henan Cancer Hospital
Zhengzhou, China · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.